menu

Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS

close
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Comments
  • Overview

    The European Commission (EC) has granted authorization of MAVENCLAD® 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis* (RMS)[1] in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity.

    To learn more about current and future treatment options for MS patients, click here.

Facebook Comments

Recommended
Details
Comments
  • Overview

    The European Commission (EC) has granted authorization of MAVENCLAD® 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis* (RMS)[1] in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity.

    To learn more about current and future treatment options for MS patients, click here.

Facebook Comments

Programs 6/24/21